Evogene
EVGN
42 hedge funds and large institutions have $24M invested in Evogene in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 9 closing their positions.
0.47% less ownership
Funds ownership: 2.29% → 1.82% (-0.47%)
7% less funds holding
Funds holding: 45 → 42 (-3)
18% less call options, than puts
Call options by funds: $722K | Put options by funds: $879K
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
43% less capital invested
Capital invested by funds: $42M → $24M (-$18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$482K |
| 2 |
Renaissance Technologies
New York
|
+$375K |
| 3 |
Jane Street
New York
|
+$158K |
| 4 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
+$110K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
+$108K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.36M |
| 2 |
SM
Senvest Management
New York
|
-$1.12M |
| 3 |
Millennium Management
New York
|
-$859K |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$200K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$168K |
EVGN Hedge Fund Activity: Q2 2021 in Review
42 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2021, worth a combined $24M — down 43% from $42M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of EVGN and 6 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 14 added.
The largest buyer was Morgan Stanley, adding an estimated $482K. The largest seller was ARK Investment Management, cutting an estimated $2.36M.
- 42 institutional investors held Evogene (EVGN) as of Q2 2021, down from 45 in Q1 2021.
- Funds reported $24M of Evogene stock for Q2 2021, down 43% quarter-over-quarter.
- 6 funds opened new Evogene positions in Q2 2021 and 9 closed out, a net change of -3 holders.
- The largest Evogene buyer in Q2 2021 was Morgan Stanley, an estimated $482K added.
- The largest Evogene seller in Q2 2021 was ARK Investment Management, an estimated $2.36M sold.
Based on aggregated 13F filings for Q2 2021.